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Since	  the	  approval	  of	  recombinant	  insulin	  from	  Escherichia	  coli	  for	  its	  clinical	  use	  in	  the	  early	  80’s,	  the	  19	  
amount	   of	   recombinant	   pharmaceutical	   proteins	   obtained	   by	   microbial	   fermentations	   has	  20	  
significantly	   increased.	   The	   recent	   advances	   in	   genomics	   together	   with	   high	   through-­‐put	   analysis	  21	  
techniques	  (the	  so-­‐called	  –omics	  approaches)	  and	  integrative	  approaches	  (systems	  biology)	  allow	  the	  22	  
development	   of	   novel	   microbial	   cell	   factories	   as	   valuable	   platforms	   for	   large	   scale	   production	   of	  23	  
therapeutic	  proteins.	  This	  review	  summarizes	  the	  main	  achievements	  and	  the	  current	  situation	  in	  the	  24	  
field	   of	   recombinant	   therapeutics	   using	   yeast	   Saccharomyces	   cerevisiae	   as	   a	  model	   platform,	   and	  25	  
discusses	  the	  future	  potential	  of	  this	  platform	  for	  production	  of	  blood	  proteins	  and	  substitutes.	  26	  
Introduction	  27	  
	  28	  
Microorganisms	   have	   been	   extensively	   used	   since	   ancient	   times	   for	   the	   production	   of	   fermented	  29	  
food	  and	  beverages,	  thousands	  of	  years	  before	  the	  actual	  nature	  of	  the	  fermentative	  processes	  was	  30	  
known.	   In	   the	  early	  20th	  century	   the	  production	  of	  citric	  acid	  based	  on	  microbial	   fermentation	  was	  31	  
initiated	  as	  the	  first	  large	  scale	  fermentation	  product	  and	  this	  was	  followed	  by	  industrial	  production	  32	  
of	  penicillin	  as	  the	  first	  antibiotic.	  Introduction	  of	  the	  genetic	  engineering	  in	  the	  70’s	  paved	  the	  way	  33	  
for	   the	   establishment	   and	   development	   of	   the	   current	   biotech	   industry,	   allowing	   the	   commercial	  34	  
production	   of	   industrial	   enzymes	   and	   biopharmaceutical	   proteins.	   In	   1980,	   the	   FDA	   approved	   for	  35	  
clinical	   use	   the	   recombinant	   insulin	   obtained	   from	   E.	   coli,	   becoming	   the	   first	   recombinant	  36	  
pharmaceutical	   protein	   to	   enter	   the	  market	   [1].	   Since	   then,	   the	  biotechnology	   industry	   has	   grown	  37	  
substantially,	   and	   currently	   about	   25%	   of	   commercial	   pharmaceuticals	   are	   biopharmaceuticals	   [2]	  38	  
with	  2010	  sales	  exceeding	  USD100	  billions	  [3].	  About	  half	  of	  the	  world-­‐wide	  sales	  are	  in	  the	  USA	  with	  39	  
monoclonal	   antibodies	   representing	   the	  majority	   (>USD18	   billions)	   followed	   by	   hormones	   (USD11	  40	  
billions)	  and	  growth	  factors	  (>USD10	  billions)[4].	  Together	  with	  the	  production	  of	  industrial	  enzymes,	  41	  
the	   recombinant	   protein	   production	   market	   is	   expected	   to	   rise	   to	   169	   billion	   dollars	   in	   2014	   [3]	  42	  
(Figure	  1).	  43	  
	  44	  
Platforms	  for	  production	  of	  pharmaceutical	  proteins	  45	  
	  46	  
Industrial	  biotechnology	  has	   traditionally	  used	  numerous	  bacterial	  and	  eukaryal	  cells	  as	  production	  47	  
platforms,	   with	   the	   main	   criterion	   for	   host	   selection	   being	   the	   ability	   to	   produce	   the	   desired	  48	  
compound.	   However,	   with	   the	   advent	   of	   genetic	   engineering	   it	   became	   possible	   to	   introduce	  49	  
heterologous	  genes	  and	  create	  new	  traits	  in	  non-­‐natural	  producers,	  allowing	  the	  development	  of	  cell	  50	  
factories	   for	   the	   production	   of	   chemicals	   through	   metabolic	   engineering.	   E.	   coli	   was	   the	   earliest	  51	  
3	  
	  
platform	  to	  be	  exploited,	  and	  is	  still	  nowadays	  the	  most	  used	  production	  platform	  for	  recombinant	  52	  
proteins	  [5],	  covering	  approx.	  30%	  of	  the	  total	  production	  of	  recombinant	  proteins	  [1]	  (Figure	  1).	  In	  53	  
general	   terms,	   bacteria	   have	   been	   considered	   to	   be	   the	  most	   efficient	   producers	   of	   heterologous	  54	  
proteins	   due	   to	   several	   reasons:	   i)	   well	   developed	   molecular	   tools	   for	   genetic	   manipulation,	   ii)	  55	  
annotated	   genomes	   and	  metabolic	   pathways,	   iii)	   high	   cell	   density	   cultivation	   capacity	   and	   growth	  56	  
rate	  and	  iv)	  high	  yield	  of	  recombinant	  proteins,	  up	  to	  80%	  of	  its	  dry	  weight	  [6-­‐8].	  However,	  standard	  57	  
prokaryotic	  systems	  have	  some	  limitations	  for	  production	  of	  human	  proteins.	  For	  example,	  bacteria	  58	  
are	   unable	   to	   perform	   some	   of	   the	   complex	   post-­‐translational	   modifications	   [1],	   which	   itself	  59	  
represents	   a	   limitation,	   since	  many	   proteins	   require	   further	   processing	   to	   become	   fully	   active.	   In	  60	  
particular	   glycosylations	   that	   are	   needed	   to	   ensure	   proper	   function	   and	   activity,	   by	   influencing	  61	  
proper	   charge,	   solubility,	   folding,	   serum	   half	   live	   of	   the	   protein,	   in	   vivo	   activity,	   correct	   cellular	  62	  
targeting	   and	   immunogenicity,	   among	   others,	   cannot	   be	   often	   be	   fully	   accomplished	   in	   bacterial	  63	  
systems	  [9]	   [10].	  These	   limitations	  have	  paved	  the	  way	  towards	  eukaryotic	  expression	  systems	  and	  64	  
there	   exists	   several	   eukaryotic	   systems	   that	   are	   currently	   in	   use	   for	   large	   scale	   production	   of	  65	  
different	   therapeutic	   proteins	   (Table	   1),	   with	   the	   most	   studied	   being	   hybridoma	   cells,	   Chinese	  66	  
Hamster	   Ovary	   (CHO)	   cells	   [11],	   insect	   cells	   [12,13]	   and	   yeast	   cells	   [14].	  Mammalian	   systems	   like	  67	  
hybridoma	  and	  CHO	  cells	  clearly	  have	  the	  highest	  similarity	  to	  human	  cells,	  and	  proteins	  produced	  by	  68	  
these	  systems	  are	  often	  properly	  folded	  and	  glycosylated.	  However	  the	  costs	  for	  their	  cultivation	  are	  69	  
high	   (e.g.	   expensive	  media	   and	   growth	   factors,	   contaminations	  with	  microorganisms	   and	   viruses),	  70	  
they	   have	   a	   limited	   secretion	   capacity	   and	   protein	   yields	   are	   usually	   low	   [15].	   On	   the	   other	   hand	  71	  
fungal	  expression	  systems,	  and	   in	  particular	  yeast,	  can	  grow	  in	  relatively	  cheap	  and	  defined	  media,	  72	  
decreasing	   the	   production	   costs.	   Besides,	   they	   are	   not	   so	   susceptible	   to	   contaminations	   and	   in	  73	  
addition,	  the	  yeast	  cells	  are	   less	  sensitive	  since	  the	  wall	  makes	  them	  more	  resistant	  to	  shear	  stress	  74	  
during	   the	   production	   process	   [10].	   Yeast	   expression	   systems	   also	   provide	   higher	   protein	   titers	  75	  
(>1g/l)	  in	  fermentation	  processes	  that	  even	  last	  shorter	  time	  (only	  few	  days)	  [16].	  Based	  on	  this,	  we	  76	  
propose	  yeast	  as	  an	  attractive	  choice,	  and	  recent	  advances	  in	  genetic	  and	  metabolic	  engineering,	  and	  77	  
tools	  in	  genomics	  and	  systems	  biology	  could	  make	  S.	  cerevisiae	  a	  preferred	  production	  platform	  for	  a	  78	  
range	   of	   pharmaceutical	   proteins[17].	   However,	   even	   though	   yeasts	   are	   eukaryotic	   systems,	   the	  79	  
glycosylations	   of	   proteins	   may	   differ	   substantially	   from	   that	   performed	   by	   mammalian	   cells,	   a	  80	  
difference	  that	  can	  be	  in	  some	  cases	  detrimental	  for	  its	  subsequent	  therapeutic	  use.	  N-­‐glycosylation	  81	  
in	   yeast,	   for	   example,	   is	   of	   the	   high	   mannose	   type	   whereas	   human	   N-­‐glycans	   are	   mainly	   of	   the	  82	  
complex	  or	  hybrid	  type.	  In	  addition	  to	  N-­‐glycosylation,	  yeast	  O-­‐glycosylation	  characterized	  by	  shorter	  83	  
glycan	   structures,	   also	   differs	   from	   the	   human	   type,	   which	   is	   mucin-­‐type	   in	   contrast	   to	   the	  84	  
oligomannosyl-­‐glycans	   in	   yeasts	   [10].	   Very	   promising	   attempts	   have	   been	   recently	   achieved	   to	  85	  
introduce	  human	  glycosylation	  patterns	   in	   yeast	   (humanized	   yeast	  platforms).	   To	  date,	   only	  Pichia	  86	  
4	  
	  
species	   have	   been	   successfully	   engineered	   to	   produce	   specific	   human-­‐like	   glycoforms	   of	   proteins,	  87	  
however	   recent	   advances	   reported	   in	   this	   field	   in	  S.	   cerevisiae	   seem	   to	   indicate	   that,	  with	   further	  88	  
development,	   it	   may	   increase	   the	   array	   of	   strains	   available	   that	   are	   able	   to	   produce	   human-­‐type	  89	  
glycosylated	   proteins,	   and	   these	   strains	   will	   become	   a	   valuable	   platform	   for	   the	   production	   of	  90	  
glycoproteins	  for	  therapeutic	  use	  [10,18,19].	  	  91	  
	  92	  
How	  to	  make	  Saccharomyces	  cerevisiae	  a	  better	  producer	  of	  pharmaceutical	  proteins?	  93	  
	  94	  
	  95	  
The	   technology	   for	   industrial	  production	  of	   recombinant	  pharmaceutical	  proteins	   in	  S.	   cerevisiae	   is	  96	  
well	  established	  and	  currently	  applied	  for	  production	  of	  human	  insulin,	  hepatitis	  virus	  vaccines	  and	  97	  
human	  papilloma	  virus	  vaccines,	  and	  its	  potential	  to	  be	  used	  for	  large	  scale	  production	  of	  many	  other	  98	  
proteins	   in	   the	   forthcoming	   years	   is	   therefore	   high.	   Furthermore,	   the	   advent	   of	   systems	   biology	  99	  
allowing	   global	   metabolism	   analysis	   and	   the	   application	   of	   so-­‐called	   “omics”	   approaches	   such	   as	  100	  
transcriptome,	  proteome	  and	  metabolome	  data,	  facilitates	  the	  identification	  of	  the	  bottlenecks	  and	  101	  
factors	  limiting	  the	  full	  potential	  of	  this	  yeast	  to	  become	  a	  better	  producer	  [20,21],	  and	  consequently	  102	  
the	   application	   of	   metabolic	   engineering	   to	   overcome	   constraints	   in	   productivity	   could	   definitely	  103	  
allow	   the	   establishment	   of	   S.	   cerevisiae	   as	   a	   suitable	   platform	   for	   large	   scale	   production	   of	  104	  
heterologous	  (including	  human)	  proteins	  [22].	  	  105	  
	  106	  
There	  are	  several	  reports	  describing	  how	  either	  genetic	  or	  metabolic	  engineering	  can	  be	  successfully	  107	  
performed	   in	   S.	   cerevisiae	   [22,23]	   resulting	   in	   the	   generation	   of	   strains	   showing	   an	   enhanced	  108	  
production	   capacity	   of	   heterologous	   proteins	   [17,24,25].	   Often	   just	   introducing	   an	   entire	   new	  109	  
pathway	   for	   the	  production	  of	   the	  desired	   compound	  does	  not	   result	   in	  high	   levels	  of	  production.	  110	  
because	  protein	  folding	  and	  secretion	  can	  represent	  the	  major	  limitation	  in	  terms	  of	  protein	  yields	  in	  111	  
yeast	   [20].	   Folding	   and	   secretion	   are	   complex	   processes	   and	   the	   molecular	   machineries	   are	  112	  
composed	   of	   large	   number	   of	   components,	   so	   further	   modifications	   and	   development	   of	   these	  113	  
pathways	   requires	   integrative	   analysis	   of	   the	   whole	   secretory	   pathway.	   Such	   approach	   has	   been	  114	  
successfully	   carried	   out	   by	   engineering	   different	   elements	   of	   the	   secretory	   pathway,	   and	   by	  115	  
combining	   different	   expression	   systems	   in	   order	   to	   optimize	   the	   production	   of	   several	   kinds	   of	  116	  
different	   proteins	   showing	   different	   biochemical	   properties	   (i.e.	   size,	   type	   of	   modification	  117	  
(glycosylation	   and/or	   disulfide	   bond	   formation)),	   such	   as	   human	   insulin	   precursor	   or	   α-­‐amylase	  118	  
[17,26,27].	   Through	   a	   combination	   of	   these	   approaches	   it	   is	   possible	   to	   select	   the	   best	   protein	  119	  
producers	  for	  further	  optimization,	  and	  this	  may	  lead	  to	  generic	  protein	  producing	  strains	  that	  can	  be	  120	  
used	  as	  general	  platforms	  for	  the	  production	  of	  bio-­‐based	  pharmaceutical	  proteins	  (Figure	  2).	  121	  
Production	  of	  Recombinant	  Human	  Blood	  Proteins	  	  122	  
5	  
	  
Among	  the	  58	  biopharmaceuticals	  approved	  in	  the	  United	  States	  and/or	  Europe	  from	  2006	  to	  2010	  123	  
four	   are	   blood	   related	   proteins,	   including	   a	   rh	   coagulation	   factor	   VIII	   produced	   in	   CHO	   cells,	   a	   rh	  124	  
antithrombin	  from	  milk	  of	  transgenic	  goats,	  a	  plasma	  kallikrein	  inhibitor	  produced	  in	  Pichia.	  pastoris,	  125	  
and	  a	  rh	  thrombin	  produced	  in	  CHO	  cells	  [28].	  All	  have	  therapeutic	  use	  for	  treatment	  of	  hemophilia.	  126	  
To	  date,	  most	  of	  the	  recombinant	  blood	  related	  biopharmaceuticals	  approved	  for	  clinical	  treatment	  127	  
are	  coagulation	  factors,	  including	  factor	  VIII,	  factor	  VIIa,	  and	  factor	  XI	  [28]	  with	  recombinant	  human	  128	  
serum	   albumin	   (rHSA)	   as	   an	   exception.	   Due	   to	   the	   fact	   that	   it	   is	   not	   glycosylated,	   a	   variety	   of	  129	  
expression	  hosts	  have	  been	  screened	  to	  express	  rHSA,	   including	  bacterium	  Bacillus	  subtilis,	  yeast	  S.	  130	  
cerevisiae,	  Kluyveromyces.	  lactis	  and	  P.	  pastoris	  etc	  [29].	  So	  far,	  Novozymes	  has	  commercialized	  two	  131	  
rHSA	  produced	  by	  S.	  cerevisiae,	  namely	  Recombumin	  and	  Albucult.	  Since	  the	  clinical	  dosage	  of	  HSA	  is	  132	  
usually	  quite	  high,	  normally	  over	  10g/L,	  many	  studies	  have	  tried	  to	  express	  rHSA	  also	   in	  P.	  pastoris	  133	  
for	  its	  high	  capacity	  in	  heterologous	  protein	  production	  [30].	  The	  rHSA	  produced	  from	  P.	  pastoris	  has	  134	  
gone	  through	  the	  clinical	  trials	  and	  confirmed	  the	  safety	  and	  efficacy	  to	  treat	  different	  diseases	  [31].	  	  135	  
	  136	  
Aside	   from	   rHSA,	  many	  other	   human	  blood	  proteins	   are	   also	   under	   active	   studies	   [32-­‐34].	  Human	  137	  
fibrinogen	  (Hf)	  is	  a	  large	  plasma	  glycoprotein	  that	  plays	  a	  critical	  role	  in	  the	  last	  stage	  of	  coagulation.	  138	  
It	   is	   dimeric	   and	   comprised	  of	   two	   sets	  of	   three	  different	  polypeptides,	   namely	  Aα,	  Bβ	  and	   γ.	   The	  139	  
protein	  was	  expressed	   in	  P.	  pastoris	  protease	  deficient	   strain	  by	   constructing	  an	  expression	  vector	  140	  
containing	  the	  cDNA	  of	  three	  individual	  peptide	  chains.	  Even	  though	  the	  peptides	  expressed	  were	  of	  141	  
different	  N-­‐glycosylation	  patterns	  as	  that	  of	  native	  Hf,	  they	  were	  correctly	  assembled	  to	  a	  functional	  142	  
rHf	   that	   is	   capable	   of	   forming	   a	   clot	   	   in	   the	   presence	   of	   factor	   XIIIa	   [32].	   Human	   α-­‐1-­‐antitrypsin	  143	  
(hAAT)	  was	  produced	  in	  tomato:	  the	  codon	  modified	  cDNA	  sequence	  was	  expressed	  and	  the	  mRNA	  144	  
5‘	   and	   3‘	   flanking	   regions	   were	  modified	   to	   achieve	   a	   high-­‐level	   expression	   by	   eliminating	  mRNA	  145	  
destabilizing	  sequences,	  which	  are	  ATTTA	  and	  its	  variants,	  splice	  sites	  and	  A/T	  strings.	  	  In	  contrast	  to	  146	  
the	   unglycosylated	   rAAT	   expressed	   in	   E.	   coli,	   the	   glycosylated	   rATT	   from	   transgenic	   tomato	   was	  147	  
biologically	  active	  [33].	  One	  more	  example	  is	  the	  production	  of	  human	  transferrins	  (Tf)	  which	  are	  a	  148	  
family	   of	  monomeric	   proteins	   that	   are	  of	   different	   sizes	  depending	  on	   the	  extent	  of	   glycosylation.	  149	  
Besides	   its	  central	  role	  to	  facilitate	   iron	  transport	  and	  metabolism,	  a	   lot	  more	  other	  functions	  have	  150	  
been	  evidenced,	   e.g.	   acting	   as	   a	   growth	   factor	   for	  mammalian	   tissue	   cells,	   as	   a	   neurotropic	   factor	  151	  
during	   neural	   stem	   cell	   development	   and	   as	   an	   angiogenic	   factor	   to	   promote	   endothelial	   cell	  152	  
migration	  etc,	  enabling	  a	  development	  of	  many	  novel	  practical	  applications	  in	  medicine	  [34].	  To	  date,	  153	  
several	  heterologous	  systems	   including	  E.	  coli,	  yeast,	   transgenic	  plants,	  mammalian	  and	   insect	  cells	  154	  
have	  been	  developed	  for	  rhTf	  production	  [34],	  among	  which	  E.	  coli	  was	  reported	  to	  be	  inefficient	  due	  155	  
to	  the	  production	  of	  inactive	  hTf.	  Successful	  expressions	  of	  hTf	  were	  reported	  in	  S.cerevisiae	  and	  P.	  156	  
6	  
	  
pastoris	  with	  the	  resulting	  proteins	  being	  functional	  independent	  of	  use	  of	  only	  a	  partial	  sequence	  or	  157	  
a	  full	  sequence,	  or	  with	  mutated	  glycosylation	  sites	  [34].	  	  	  158	  
	  159	  
S.	  cerevisiae	  as	  a	  cell	  factory	  for	  human	  hemoglobin	  production	  160	  
All	  the	  proteins	  described	  above	  are	  blood	  plasma	  components	  which	  contribute	  to	  different	  roles	  of	  161	  
blood	   such	   as	   coagulation,	   clotting,	   transport	   of	   iron,	  maintain	   blood	   osmotic	   pressure	   and	   blood	  162	  
volume.	  The	  additional	   crucial	   role	  of	  blood	   is	   the	   transport	  of	  oxygen	  and	   the	  only	   component	   in	  163	  
blood	   that	   possesses	   oxygen	   carrier	   function	   is	   hemoglobin	   (found	   in	   erythorcytes),	   and	   this	   is	  164	  
therefore	  a	  key	  component	   for	  development	  of	  human	  blood	  substitutes	   for	   treatment	  of	  patients	  165	  
with	  injuries,	  anemia	  or	  in	  post-­‐operational	  recovery.	  166	  
Production	  of	   recombinant	   hemoglobin	   (rHb)	   has	   been	   attempted	   since	   the	   late	   80’s.	   A	   variety	   of	  167	  
strategies	   have	   been	   applied	   using	   several	   different	   expression	   systems,	   ranging	   from	   bacteria	   to	  168	  
higher	  organisms	  such	  as	  transgenic	  plants	  and	  animals	  [35].	  The	  work	  was	  first	  done	  in	  E.	  coli,	  where	  169	  
a	  single	  β	  globin	  was	  expressed	  with	  a	  cleavable	  linker	  and	  refolded	  in	  vitro	  with	  native	  α	  globin	  and	  170	  
exogenous	  heme	  [35].	  The	  work	  was	  quite	  laborious	  and	  researchers	  therefore	  tried	  to	  express	  α	  and	  171	  
β	  globins	  simultaneously	  in	  vivo	  with	  endogenous	  heme	  incorporated	  [36].	  It	  was	  observed	  that	  the	  172	  
essential	  parameters	  for	  normal	  human	  hemoglobin,	  namely	  Bohr	  effect	  and	  2,3-­‐BPG	  effects	  of	  the	  173	  
rHb	  were	   reduced	  which	  very	   likely	   resulted	   from	  the	  methionine	   termini	  at	   the	  end	  of	   the	  globin	  174	  
chains	   [37].	  The	  amount	  of	  methionine	  modified	  α	  and	  β	  globins	  were	  significantly	   reduced	  by	  co-­‐175	  
expression	  of	   the	  methionine	  amino-­‐peptidase	   (Met-­‐AP)	  gene	  with	   the	  globin	  genes	   resulted	   in	  an	  176	  
increased	   yield	   of	   rHb	   [36].	   Further	   optimizations	   of	   the	  E.	   coli	   expression	   system	   included	   codon	  177	  
optimization	  for	  globin	  expression	  in	  a	  T7	  promoter	  system	  [38];	  Site-­‐directed	  mutations	  in	  β	  globin	  178	  
chain	  in	  order	  to	  reduce	  the	  extreme	  oxygen	  affinity	  to	  rHb	  (no	  release	  of	  oxygen)	  due	  to	  the	  lack	  of	  	  179	  
2,	   3-­‐BPG	   allosteric	   regulation;	   and	   a	   tandem	   fused	   α	   globin	   to	   prevent	   the	   dissociating	   of	   the	  180	  
tetramer	  into	  a	  αβ	  dimer	  [39].	  In	  some	  resent	  studies,	  researchers	  have	  tried	  to	  co-­‐express	  α	  globin	  181	  
with	   its	  molecular	   chaperon,	  α-­‐hemoglobin	   stabilizing	  protein	   (AHSP)	  and	   revealed	   its	  mechanisms	  182	  
on	  preventing	  α	  globin	  precipitation.	  [40-­‐42].	  Correct	  expression	  and	  folding	  of	  human	  Hb	  have	  also	  183	  
been	  accomplished	  in	  animals,	  e.g.	  pig	  [43]	  and	  mice	  [44,45],	  and	  in	  plants,	  e.g.	  tobacco[46].	  	  184	  
	  185	  
The	   previous	   examples	   and	   the	   state-­‐of-­‐the-­‐art	   methodologies	   and	   approaches	   show	   that	   S.	  186	  
cerevisiae	   can	   be	   engineered	   to	   become	   an	   even	   better	   producer	   for	   a	   wider	   range	   of	  187	  
pharmaceutical	   and	   blood	   proteins.	   Comparing	   to	   E.	   coli,	   heterologous	   proteins	   produced	   in	   S.	  188	  
cerevisiae	   do	  not	  have	  methionine	  modification	  which	   affecting	   the	  biological	   function	  of	   the	   rHb.	  189	  
7	  
	  
Compared	   to	   plant	   and	   animal	   expression	   systems,	   the	   yeast	   system	   is	   cheaper	   and	   faster	   to	  190	  
manipulate.	  As	  an	  outlook,	  we	  propose	  several	  potential	  strategies	  for	  increasing	  human	  hemoglobin	  191	  
production	  in	  S.	  cerevisiae	  e.g.	  globin	  folding,	  heme	  uptake,	  and	  subunit	  assembling.	  192	  
	  193	  
Additionally	  to	  the	  existing	  strategies	  such	  as	  site	  directed	  mutagenesis	  of	  the	  amino	  acids	  that	  are	  194	  
important	   for	   stabilization	   [47,48],	   co-­‐overexpression	   of	   α	   and	   β	   globin	   genes,	   cross-­‐linking	   two	  α	  195	  
globins	  as	  di-­‐α	  to	  avoid	  αβ	  dimer	  formation,	  it	  is	  worth	  trying	  to	  co-­‐express	  the	  AHSP	  gene	  together	  196	  
with	  the	  α	  and	  β	  globin	  genes	  to	  increase	  the	  α	  globin	  stability	  [42,49,50]	  thus	  further	  enhancing	  the	  197	  
production	  of	  rHb.	  	  It	  has	  also	  been	  reported	  that	  heme	  can	  accelerate	  hemoglobin	  accumulation	  in	  198	  
immature	  cultured	  erythroid	  cells	  [51]	  and	  heme	  is	  not	  only	  the	  indispensable	  prosthetic	  group	  but	  199	  
also	   essentially	   involved	   in	   assembling	   and	   ensuring	   a	   stable	   tetramer	   structure	   [52].	   As	   heme	  200	  
supplementation	  is	  expensive	  and	  the	  mechanism	  behind	  is	  poorly	  understood	  [53],	  engineering	  the	  201	  
heme	   synthesis	   pathway	   is	   proposed	   to	   be	   a	   better	   choice	   to	   increase	   heme	   levels	   in	   the	   cell.	  202	  
Examples	  for	  engineering	  the	  heme	  biosynthesic	  pathway	  include	  over-­‐expression	  of	  the	  rate-­‐limiting	  203	  
enzymes	  in	  the	  synthesis	  pathway	  [54],	  engineering	  ALA	  (aminolevulinic	  acid)	  synthesis	  since	  it	  is	  the	  204	  
first	  intermediate	  involved	  in	  heme	  synthesis,	  as	  well	  as	  engineering	  the	  iron	  uptake	  pathway.	  	  205	  
In	   conclusion,	   the	   recent	   advances	   in	   the	   field	   of	  metabolic	   engineering	   allowed	   that	  S.	   cerevisiae	  206	  
become	  an	  efficient	   cell	   factory	   for	   the	  production	  of	  heterologous	  proteins.	  By	  a	   systems	  biology	  207	  
approach,	   further	   improvements	   might	   be	   implemented	   through	   integrative	   analysis	   and	   the	  208	  
development	  of	  mathematical	  predictive	  models,	  being	  this	  yeast	  expected	  to	  become	  the	  suitable	  209	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Figure	   1.	   (A)	   Global	   market	   for	   recombinant	   protein	   drugs	   and	   (B)	   percentage	   of	   protein-­‐based	  423	  






Figure	   2.	  Workflow	  overview	   for	   the	  development	  of	   yeast	   cell	   factories	   by	  metabolic	   engineering	  428	  
from	   a	   systems	   biology	   approach.	   Engineering	   for	   protein	   production	   improvement	   can	   be	  429	  
implemented	  either	  at	  a	  host	  level	  (e.g.	  metabolic	  engineering	  of	  gene	  pathways	  related	  to	  different	  430	  
steps	   concerning	   protein	   processing	   and	   secretion)	   and/or	   be	   applied	   to	   the	   improvement	   of	  431	  
expression	   systems	  by	   addition/testing	   of	   different	   features	   (e.g.	   the	   suitable	   selection	  marker	   for	  432	  
each	   system,	   promoter	   sequences,	   etc).	   High	   throughput	   analysis	   methodologies	   allow	   then	   the	  433	  
generation	  or	  large	  data	  sets,	  which	  can	  be	  processed	  and	  integrated	  in	  mathematical	  models	  for	  the	  434	  
identification	  of	  new	  potential	  targets,	  allowing	  further	  improvement	  via	  retrofitting	  the	  system,	  and	  435	  








Protein	   System	   Production	  level	   Refs	  
Hirudin	   S.	  cerevisiae	  (Y)	  





Interferon	  α-­‐2b	   H.	  polymorpha	  (Y)	   120	  mg/L	   [57]	  
Hepatitis	  B	  vaccine	   H.	  polymorpha	  (Y)	   -­‐	   [58]	  
Angiostatin	   P.	  pastoris	  (Y)	   108	  mg/L	   [59]	  
Anti-­‐HBs	  Fab	   P.	  pastoris	  (Y)	   50	  mg/L	   [60]	  
Human	  serum	  albumin	   K.	  lactis	  (Y)	  
S.	  cerevisiae	  (Y)	  







Human	  interleukin	  6	   A.	  niger	  (F)	   150	  mg/L	   [64]	  
Human	  apolipoprotein	  AI	   CHO	  cells	  (M)	   80	  mg/ml	   [65]	  
Insulin	  precursor	   P.	  pastoris	  (Y)	  





Human	  tPA	   CHO	  cells	  (M)	   34	  mg/L	   [67]	  
Human	  gonadotropin	   CHO	  cells	  (M)	   3	  g/L	   [67]	  
Erythropoietin	  (epoetin	  α)	   CHO	  cells	  (M)	   -­‐	   [68]	  
14	  
	  
Monoclonal	  Ab	   NSO	  cells	  (M)	   3	  g/L	   [67]	  
HPV	  vaccine	  (CervarixTM)	   Insect	  cells	  	   -­‐	   [69]	  
Human	  proapolipoprotein	  AI	   Insect	  cells	   80	  mg/L	   [70]	  
Clotting	  factor	  VII	  a	   BHK	  cells	  (M)	   -­‐	   [68]	  
	  444	  
Table	   1.	   Examples	   of	   recombinant	   therapeutic	   proteins	   successfully	   expressed	   using	   different	  445	  
production	   systems,	   including	  highest	  production	   levels	   reported	   in	  each	  organism.	  CHO	  =	  Chinese	  446	  
hamster	   ovary	   cells;	   BHK	   =	   Baby	   hamster	   kidney	   cells;	   NSO	   =	   Myeloma	   cells;	   (Y)	   =	   Yeast;	   (F)	   =	  447	  
Filamentous	  fungi;	  (M)	  =	  Mammalian.	  448	  
	  449	  
Hightlights	  450	  
Recombinant	  therapeutic	  production	  is	  a	  multibillion	  dollar	  market.	  451	  
E.	  coli	  represents	  30%	  of	  recombinant	  protein	  production	  but	  not	  suitable	  for	  human	  therapeutics.	  	  452	  
Eukaryotic	  systems	  other	  than	  yeast	  are	  costly	  or	  not	  so	  efficient	  regarding	  protein	  yields.	  	  453	  
S.	  cerevisiae	  shows	  a	  high	  potential	  to	  be	  a	  suitable	  platform	  for	  therapeutic	  protein.	  454	  
Human	  blood	  proteins	  are	  the	  next	  candidates	  to	  be	  challenged	  by	  S.	  cerevisiae	  system.	  	  455	  
	  456	  
	  457	  
